ValuentumAd

Official PayPal Seal
Valuentum Reports













Fundamental data is updated weekly, as of the prior weekend. Please download the Full Report and Dividend Report for any changes.
Latest Valuentum Commentary

Jul 31, 2014
Teva: Progressing As Expected; US Generic Revenue Reveals Strength
The generics pharma giant has been one of the best performing stocks during 2014, up nearly 34% year-to-date.
Jul 30, 2014
Big Pharma Round Up
Let’s take a look at recent quarterly results from Big Pharma.
Jul 17, 2014
Abbott Ups Guidance; Takes Stake in Mylan
We think Abbott is a tried and true dividend growth stock. Let’s take a look at recent events at the firm.
Jun 22, 2014
Valuentum Economic Castle™ Rating Update
Members should expect the initial Economic Castle™ ratings.
Apr 17, 2014
Expect Abbott to Raise Its 2014 Outlook Soon
Abbott’s first-quarter results weren’t pristine, but the company’s better-than-expected first-quarter performance will eventually lead to an upwardly-revised full-year outlook, in our view.
Mar 21, 2014
Update: Digging Into the Valuentum Dividend Cushion
We explain our innovative, predictive, and forward-looking indicator that assesses the safety of a firm's future dividends. The Valuentum Dividend Cushion flashed a red flag for every firm that cut their dividend in our database.
Feb 17, 2014
Deciphering Valuentum’s Dividend Lingo
Let’s examine how some investors are using the framework behind the Valuentum Dividend Cushion, if not the measure itself.
Jan 27, 2014
Surveying Fourth Quarter Earnings at Health Care Firms
Though it may be difficult to focus on underlying equity fundamentals in the face of a volatile overall market environment, we think doing so is even more important under such circumstances. Let’s examine our thoughts on fourth-quarter earnings season in the health care space .
Oct 20, 2013
Third-Quarter Industrial Earnings Support Exposure in Best Ideas Portfolio
A number of industrial firms’ calendar third-quarter earnings are out. Let’s take a look at how our Best Ideas portfolio is well-positioned to capture the strength of underlying trends.
Oct 16, 2013
Abbott’s Expansion Slowed By Supplier Recall; Raises Dividend
Abbott’s results would have been even better were it not for a supplier recall in its ‘Nutrition’ business.


Latest News and Media
The High Yield Dividend Newsletter, Best Ideas Newsletter, Dividend Growth Newsletter, Nelson Exclusive publication, and any reports, articles and content found on this website are for information purposes only and should not be considered a solicitation to buy or sell any security. The sources of the data used on this website are believed by Valuentum to be reliable, but the data’s accuracy, completeness or interpretation cannot be guaranteed. Valuentum is not responsible for any errors or omissions or for results obtained from the use of its newsletters, reports, commentary, or publications and accepts no liability for how readers may choose to utilize the content. Valuentum is not a money manager, is not a registered investment advisor and does not offer brokerage or investment banking services. Valuentum, its employees, and affiliates may have long, short or derivative positions in the stock or stocks mentioned on this site.